Jerkeman M, et al. - It was hypothesized that treatment of relapsed or refractory mantle cell lymphoma with the combination of ibrutinib, lenalidomide, and rituximab would provide improved efficacy compared with previously published data on either regimen alone. The current investigation offered initial proof that the triplet combination of ibrutinib, lenalidomide, and rituximab is an active regimen in patients with relapsed or refractory mantle cell lymphoma.